(Q37703202)

22 August 2017

1 reference

title

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus (English)

1 reference

22 August 2017

0 references

1

Sohita Dhillon

1 reference

22 August 2017

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

70

1 reference

22 August 2017

4

1 reference

22 August 2017

489-512

1 reference

https://scigraph.springernature.com/pub.10.2165/11203790-000000000-00000

22 August 2017

0 references

cites work

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11203790-000000000-00000

Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11203790-000000000-00000

21 January 2018

1 reference

12 December 2020

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

1 reference

12 December 2020

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

1 reference

12 December 2020

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

1 reference

12 December 2020

New treatments in type 2 diabetes: a focus on the incretin-based therapies

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Card

1 reference

12 December 2020

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

1 reference

12 December 2020

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

1 reference

12 December 2020

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

12 December 2020

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

1 reference

12 December 2020

Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus

1 reference

12 December 2020

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

12 December 2020

A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects

1 reference

12 December 2020

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

1 reference

12 December 2020

Effects of intensive glucose lowering in type 2 diabetes

1 reference

12 December 2020

Impact of sitagliptin on markers of beta-cell function: a meta-analysis

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

12 December 2020

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

1 reference

12 December 2020

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

1 reference

12 December 2020

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

12 December 2020

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

12 December 2020

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

12 December 2020

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

12 December 2020

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

1 reference

12 December 2020

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

12 December 2020

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

12 December 2020

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

1 reference

12 December 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

12 December 2020

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

1 reference

12 December 2020

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

12 December 2020

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

12 December 2020

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

1 reference

12 December 2020

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

1 reference

12 December 2020

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

12 December 2020

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

1 reference

12 December 2020

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

12 December 2020

Standards of medical care in diabetes--2009.

1 reference

12 December 2020

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

1 reference

12 December 2020

Diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

1 reference

12 December 2020

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

1 reference

12 December 2020

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

1 reference

12 December 2020

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

12 December 2020

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

12 December 2020

10.2165/11203790-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20205490

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20205490